Search

ABSTRACT Objective: Evaluate cryosurgery followed by 3.75% imiquimod cream to treat actinic keratoses (AK). Methods: Adults with [greater than or equal to] 10 AKs on the face underwent cryosurgery of [...]

ABSTRACT Background: No effective treatment exists for permanent keloid removal. When applied to excised-sites, imiquimod 5% cream reduces keloid recurrence. Case series suggest the tolerability and efficacy of imiquimod 5% [...]

ABSTRACT Background: Field-directed therapies for actinic keratosis include photodynamic therapy and imiquimod. Objectives: The author designed a randomized, vehicle-controlled, split-face study to explore the safety and efficacy of photodynamic therapy [...]

ABSTRACT Lentigo maligna (LM) is an in situ variant of cutaneous melanoma, which usually occurs in sun-damaged skin. Surgical treatment of LM is often difficult and not well accepted by [...]

ABSTRACT Basal cell carcinoma (BCC) is regarded as the most prevalent malignant skin tumor in whites. A variety of surgical and nonsurgical interventions are available lo treat BCC. In recent [...]

Abstract The short-term and long-term outcomes of 108 patients with 122 nodular basal cell carcinomas (BCCs), morpheaform BCCs, or low-risk squamous cell carcinomas (SCCs) treated with imiquimod 5% cream at [...]

Abstract The number of basal cell carcinomas (BCCs) occurring in the US in 2007 has been conservatively estimated to be 1 million. Surgical extirpation alone is the standard for the [...]

Abstract Background: Electrodesiccation and curettage is commonly used for the treatment of basal cell carcinomas (BCCs). Does the addition of imiquimod 5% cream improve clearance rates and cosmetic outcomes? Objective: [...]

Abstract Lentigo maligna (LM) is an in situ melanoma that occurs in sun-damaged skin on the head and neck of elderly patients. Surgical excision is the treatment of choice for [...]

Abstract Imiquimod, an immune response modifier approved for the treatment of external genital warts, actinic keratoses, and superficial basal cell carcinoma, can induce a severe local inflammatory response. This phenomenon [...]

ABSTRACT The immunomodulating drug imiquimod is approved by the U.S. Food and Drug Administration (FDA) to treat actinic keratoses, non-facial superficial basal cell carcinomas and genital warts. This drug elicits [...]

Byline: Aditya. Bubna Imiquimod is a synthetic imidazoquinolone amine, which has potent immune response modifier activity, when topically used. This characteristic property of imiquimod has led to its use in [...]

Abstract Bowen's disease of the penis is relatively uncommon, but the prevalence has increased in recent years. Risk factors for penile squamous cell cancer include smoking, infection with human papilloma [...]

Byline: Amol. Metkar, Sushil. Pande, Uday. Khopkar Background: There are numerous therapeutic modalities available for treatment of molluscum contagiosum. However, the ablative modalities are painful and not suitable for children. [...]

Byline: Vandana. Rai, C. Balachandran, Sudha. Bhat, V. Geetha A 55 year-old male presented to us with an asymptomatic plaque on the chest of a year's duration. There was a [...]

Byline: Smitha. Prabhu, Raghavendra. Rao, H. Sripathi, Sunaina. Hameed, Ranjini. Kuduva Sir, Bowen's disease is a rare, persistent, progressive intraepidermal carcinoma, which may be potentially malignant, with up to 8% [...]

Byline: Engin. Senel, Deniz. Seckin Sir, Imiquimod, an imidazoquinoline amine, is a potent topical immune response modifier.[sup] [1] It has been used effectively to treat human papillomavirus-induced warts, molluscum contagiosum, [...]

Byline: Kruti. Jobanputra, Aruna. Rajpal, N. Nagpur Introduction Imiquimod, a heterocyclic imidazoquinoline amide, is an immune response modifying drug that has potent antiviral and antitumor activity.[1],[2] Pharmacokinetics[1] Topical radiolabeled imiquimod [...]

Byline: Amit. Malhotra, Arika. Bansal, Asit. Mridha, Binod. Khaitan, Kaushal. Verma Imiquimod, an immune response modifier, is known to possess both anti-viral and anti-tumor effect. We report our experience of [...]

Abstract Background: Using more than one therapeutic approach in the treatment of basal cell carcinomas (BCCs) has the potential to enhance cure rates. Materials and Methods: In this study, 57 [...]

This case report describes the successful treatment of basal cell carcinomas in three patients with the nevoid basal cell carcinoma syndrome (NBCCS) with topical 5% imiquimod. NBCCS is an inherited [...]

Two separate studies were conducted to examine the effect of imiquimod 5% cream with occlusion for the treatment of basal cell cancers (BCC). Patients diagnosed with BCCs were enrolled into [...]

Perrigo Company has announced that it received FDA approval to manufacture and market Imiquimod Cream 5%, the generic equivalent of Aldara[R] Cream 5%, a topical treatment for actinic keratoses on [...]

Sponsored by MEDA Pharma GmbH & Co. KG. This clinical trial will compare the long-term effects of a treatment of actinic keratosis using Aldara[R] 5% cream or Solaraze[R] 3% gel [...]